CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma-Reference-Cited by-同舟云学术

CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma

Published:2024-08 Issue: Volume:597 Page:217080
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Wang Yali,Chen Jianfeng,Gao Yan,Chai Kelila Xin Ye^ORCID,Hong Jing Han,Wang Peili,Chen Jinghong,Yu Zhaoliang,Liu Lizhen,Huang Cheng,Taib Nur Ayuni Muhammad,Lim Kerry May Huifen,Guan Peiyong,Chan Jason Yongsheng,Huang Dachuan,Teh Bin Tean,Li Wenyu,Lim Soon Thye,Yu Qiang,Ong Choon Kiat,Huang Huiqiang,Tan Jing

Funder

Tanoto Foundation

Guangzhou Municipal Science and Technology Program key projects

Sun Yat-sen University Cancer Center

National Key Research and Development Program of China

National Medical Research Council

Lingnan Foundation

Ministry of Health -Singapore

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference54 articles.

1. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes;Ng;Haematologica,2018

2. NK-/T-cell lymphomas;Wang;Leukemia,2021

3. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study;Yamaguchi;J. Clin. Oncol.,2011

4. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study;Kim;J. Clin. Oncol.,2009

5. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China;Li;Clin. Cancer Res.,2016